This case report marks the first instance of a patient diagnosed with RET aberrant cancer exhibiting both NTRK and ALK fusions, who underwent treatment with an NTRK inhibitor and subsequently with an NTRK/ALK inhibitor. This evidence concerns the gene RET and cancer.